次世代シーケンサー市場：技術、製品タイプ、用途、エンドユーザー別-2025-2030年の世界予測

次世代シーケンサー市場は、2023年に177億3,000万米ドルと評価され、2024年には213億8,000万米ドルに達すると予測され、CAGR 23.61％で成長し、2030年には782億1,000万米ドルになると予測されています。

次世代シーケンサー（NGS）は、ゲノム全体またはDNAやRNAの特定領域の迅速なシーケンシングを可能にする一連の遺伝学的技術であり、遺伝学や疾患検出に関する重要な洞察を提供します。NGSの必要性は、ハイスループットのシーケンスデータを効率的かつ低コストで提供する能力にあり、個別化医療、遺伝子研究、さらにはアグリゲノミクスへの応用を可能にします。NGSは主に研究環境、臨床診断、生殖医療、薬理ゲノミクス、疾病管理で使用されています。最終用途は、学術、バイオテクノロジー企業、製薬、ヘルスケア施設に及ぶ。主な成長要因としては、シークエンシング技術の進歩、遺伝性疾患の有病率の上昇、官民両部門によるゲノミクスへの投資の増加などが挙げられます。個別化医療に対する需要の急増、腫瘍学や感染症検査における新たな応用は、大きなビジネスチャンスです。これらを活用するために、企業は費用対効果が高く、より迅速で正確なシーケンス技術の開発に注力し、アジア太平洋地域のようなゲノム研究インフラに投資している新興国市場に進出すべきです。とはいえ、市場の成長は、初期設定コストの高さ、遺伝子データのプライバシーに関する倫理的懸念、特に臨床応用に関する規制上のハードルといった課題に直面しています。データ解釈の限界や熟練労働者の不足も急速な普及を妨げています。イノベーションは、データ解析のためのAIと機械学習の統合、より直感的なバイオインフォマティクス・ツールの開発、配列アセンブリー精度の向上に焦点を当てるべきです。市場は、急速な技術進歩やパンデミック後の公衆衛生の優先事項の変化を反映して非常にダイナミックであり、競争力を維持するためには機敏さと研究開発への継続的な投資が必要となります。戦略的には、企業は学術研究機関との提携や、包括的なゲノムデータ解釈サービスを含むサービス提供の拡大を検討すべきであり、NGSの有用性における重要なボトルネックに対処する必要があります。

市場力学：急速に進化する次世代シーケンサー市場の主要市場インサイトを公開

次世代シーケンサー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 臨床診断におけるNGS技術の広範な採用。
  • NGSの応用が拡大し、腫瘍学研究のための資金が急増
  • 植物の遺伝的可能性を分析するための農業分野での採用の増加
• 市場抑制要因
  • 臨床データを分析・解釈するための計算リソースとスタッフの不足
• 市場機会
  • 新技術の開発とNGSベースの製品の商業化への継続的な注力
  • 大規模シーケンス技術に対する政府および民間セクターからの支援の増加
• 市場の課題
  • 次世代シーケンサーデータ保護に関する倫理的・プライバシー的懸念

ポーターの5つの力：次世代シーケンサー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、次世代シーケンサー市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：次世代シーケンサー市場における外部からの影響の把握

外部マクロ環境要因は、次世代シーケンサー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析次世代シーケンサー市場における競合情勢の把握

次世代シーケンサー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス次世代シーケンサー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、次世代シーケンサー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨次世代シーケンサー市場における成功への道筋を描く

次世代シーケンサー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 結果が早く、処理が速いため、臨床診断におけるNGS技術の広範な採用
    • NGSの応用拡大と腫瘍学調査への資金の急増
    • 植物の遺伝的可能性を分析するために農業分野で採用が拡大
  • 抑制要因
    • 臨床データを分析・解釈するための計算リソースと人員の不足
  • 機会
    • 新技術の開発とNGSベースの製品の商業化に継続的に注力
    • 大規模シーケンシング技術に対する政府と民間部門からの支援の強化
  • 課題
    • 次世代シーケンサーデータ保護に関する倫理的およびプライバシー上の懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 次世代シーケンサー市場：技術別

• ターゲットシーケンシングと再シーケンシング
• 全エクソーム配列解析
• 全ゲノム配列解析

第7章 次世代シーケンサー市場：製品タイプ別

• 消耗品
• プラットフォーム
• サービス

第8章 次世代シーケンサー市場：用途別

• 農業
• 動物科学と獣医学調査
• 診断
• 創薬

第9章 次世代シーケンサー市場：エンドユーザー別

• 学術調査機関
• 臨床検査室
• 契約調査機関
• 病院・クリニック
• 製薬・バイオテクノロジー企業

第10章 南北アメリカの次世代シーケンサー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の次世代シーケンサー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの次世代シーケンサー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • QIAGENがVerogenの買収を完了し、NGSテクノロジーによるヒト ID/法医学のリーダーシップを強化します。
  • QIAGENとHelixが、遺伝性疾患における次世代シーケンシングコンパニオン診断を推進するための独占的パートナーシップを開始しました。
  • Agilent社、がん調査向け高性能NGSターゲットエンリッチメントワークフローの開発企業Avida Biomed社の買収を発表。
  • Integrated DNA TechnologiesがInvitae CorporationからArcherDX次世代シーケンサー調査アッセイを買収。
  • MGIの一員であるComplete Genomicsが、ASHG年次会議で次世代シーケンシングプラットフォームを発表しました。
  • BGIオーストラリアが臨床全エクソーム配列解析のNATA認定を取得。
  • ASMがCDC資金提供によるゲノム監視トレーニングプログラムを発表。
  • NGSバイオセーフティ試験およびバイオ医薬品の特性評価における一流の専門家が、重要な米国市場で新たな機能を開始します。
  • イルミナが次世代DNAシーケンサーを発売。
  • サーモフィッシャーサイエンティフィックは、臨床検査室での使用向けにCE-IVDマークを取得した次世代シーケンシング装置を発売しました。
  • イルミナとトリビトロンが提携し、インドの患者の病気の検出と診断を加速します。
• 戦略分析と提言

企業一覧

• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• ATDBio Ltd.
• BGI Genomics Co., Ltd.
• Bio-Rad Laboratories, Inc.
• BIO3 SCIENTIFIC SDN BHD
• bioMerieux S.A.
• BioVendor-Laboratorni medicina a.s
• Cambridge Bioscience Limited
• CD Genomics
• CeGaT GmbH
• Charles River Laboratories, Inc.
• DNAnexus, Inc.
• DNASTAR, Inc.
• ELEMENT BIOSCIENCES
• Enzo Life Sciences, Inc.
• Eppendorf SE
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd.
• Fraunhofer-Gesellschaft
• GENEWIZ
• Genomatix
• GenPath
• GenScript Biotech Corporation
• GRAIL, LLC
• Hamilton Company
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Invivoscribe, Inc.
• iRepertoire, Inc.
• LabMal
• Macrogen, Inc.
• Medigene Sdn Bhd.
• Merck KGaA
• NanoString Technologies, Inc.
• Neoscience
• Norgen Biotek Corp.
• Oxford Nanopore Technologies PLC
• Pacific Biosciences of California, Inc.
• PathoQuest
• PCR Biosystems Ltd.
• Perkin Elmer, Inc.
• Promega Corporation
• PT Pandu Biosains
• Qiagen N.V.
• Resolution Bioscience, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. NEXT GENERATION SEQUENCING MARKET RESEARCH PROCESS
• FIGURE 2. NEXT GENERATION SEQUENCING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEXT GENERATION SEQUENCING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEXT GENERATION SEQUENCING MARKET DYNAMICS
• TABLE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING & RE-SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. CANADA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 66. INDIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. ITALY NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. ITALY NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. POLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. POLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. QATAR NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. QATAR NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023

The Next Generation Sequencing Market was valued at USD 17.73 billion in 2023, expected to reach USD 21.38 billion in 2024, and is projected to grow at a CAGR of 23.61%, to USD 78.21 billion by 2030.

Next Generation Sequencing (NGS) represents a suite of genetic technologies that allow rapid sequencing of entire genomes or specific areas of DNA or RNA, offering significant insights into genetics and disease detection. Its necessity is anchored in its ability to provide high-throughput sequencing data efficiently and at decreasing costs, enabling advances in personalized medicine, genetic research, and even applications in agrigenomics. NGS is primarily used in research settings, clinical diagnostics, reproductive health, pharmacogenomics, and disease management. The end-use spectrum spans academia, biotechnology firms, pharmaceuticals, and healthcare facilities. Key growth factors include advancements in sequencing technology, rising prevalence of genetic disorders, and increasing investments in genomics by both public and private sectors. The surge in demand for personalized medicine and new applications in oncology and infectious disease testing are significant opportunities. To capitalize on these, businesses should focus on developing cost-effective, faster, and more accurate sequencing technologies and expand into emerging markets that are investing in genomic research infrastructures, like APAC. Nonetheless, market growth faces challenges such as high initial setup costs, ethical concerns regarding genetic data privacy, and regulatory hurdles, especially concerning clinical applications. Limitations in data interpretation and lack of skilled workforce also impede rapid adoption. Innovations should focus on AI and machine learning integration for data analysis, development of more intuitive bioinformatics tools, and improvements in sequence assembly accuracy. The market is highly dynamic, reflecting rapid technological advances and shifting public health priorities post-pandemic, necessitating agility and continued investment in R&D to remain competitive. Strategically, firms should consider partnerships with academic research institutions and expansion of service offerings to include comprehensive genomic data interpretation services, addressing a key bottleneck in NGS utility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next Generation Sequencing Market

The Next Generation Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processin
  • Increased application of NGS and exponential availability of funds for oncology research
  • Emerging adoption in the agriculture sector to analyze the genetic potential of plants
• Market Restraints
  • Lack of the computational resources and staffing to analyze and interpret clinical data
• Market Opportunities
  • Continuous focus on new technology development and commercialization of NGS based products
  • Increased support from government and private sector for large scale sequencing technology
• Market Challenges
  • Ethical and privacy concerns related to next generation sequencing data protection

Porter's Five Forces: A Strategic Tool for Navigating the Next Generation Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next Generation Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next Generation Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next Generation Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next Generation Sequencing Market

A detailed market share analysis in the Next Generation Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next Generation Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next Generation Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next Generation Sequencing Market

A strategic analysis of the Next Generation Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next Generation Sequencing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Agilent Technologies, Inc., ATDBio Ltd., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., BIO3 SCIENTIFIC SDN BHD, bioMerieux S.A., BioVendor-Laboratorni medicina a.s, Cambridge Bioscience Limited, CD Genomics, CeGaT GmbH, Charles River Laboratories, Inc., DNAnexus, Inc., DNASTAR, Inc., ELEMENT BIOSCIENCES, Enzo Life Sciences, Inc., Eppendorf SE, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Fraunhofer-Gesellschaft, GENEWIZ, Genomatix, GenPath, GenScript Biotech Corporation, GRAIL, LLC, Hamilton Company, Illumina, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., iRepertoire, Inc., LabMal, Macrogen, Inc., Medigene Sdn Bhd., Merck KGaA, NanoString Technologies, Inc., Neoscience, Norgen Biotek Corp., Oxford Nanopore Technologies PLC, Pacific Biosciences of California, Inc., PathoQuest, PCR Biosystems Ltd., Perkin Elmer, Inc., Promega Corporation, PT Pandu Biosains, Qiagen N.V., Resolution Bioscience, Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next Generation Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Targeted Sequencing & Re-Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing.
• Based on Product Type, market is studied across Consumables, Platforms, and Services.
• Based on Application, market is studied across Agriculture, Animal science & Veterinary Research, Diagnostics, and Drug Discovery.
• Based on End User, market is studied across Academic & Research Institutes, Clinical Laboratories, Contract Research Organization, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processin
    • 5.1.1.2. Increased application of NGS and exponential availability of funds for oncology research
    • 5.1.1.3. Emerging adoption in the agriculture sector to analyze the genetic potential of plants
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of the computational resources and staffing to analyze and interpret clinical data
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous focus on new technology development and commercialization of NGS based products
    • 5.1.3.2. Increased support from government and private sector for large scale sequencing technology
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical and privacy concerns related to next generation sequencing data protection
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Next Generation Sequencing Market, by Technology

• 6.1. Introduction
• 6.2. Targeted Sequencing & Re-Sequencing
• 6.3. Whole Exome Sequencing
• 6.4. Whole Genome Sequencing

7. Next Generation Sequencing Market, by Product Type

• 7.1. Introduction
• 7.2. Consumables
• 7.3. Platforms
• 7.4. Services

8. Next Generation Sequencing Market, by Application

• 8.1. Introduction
• 8.2. Agriculture
• 8.3. Animal science & Veterinary Research
• 8.4. Diagnostics
• 8.5. Drug Discovery

9. Next Generation Sequencing Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Clinical Laboratories
• 9.4. Contract Research Organization
• 9.5. Hospitals & Clinics
• 9.6. Pharmaceutical & Biotechnology Companies

10. Americas Next Generation Sequencing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Next Generation Sequencing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Next Generation Sequencing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. QIAGEN completes acquisition of Verogen, strengthening leadership in Human ID / Forensics with NGS technologies.
  • 13.3.2. QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases.
  • 13.3.3. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research.
  • 13.3.4. Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation.
  • 13.3.5. Complete Genomics, part of MGI, Announces Next-Generation Sequencing Platforms at ASHG Annual Meeting.
  • 13.3.6. BGI Australia receives NATA certification for clinical whole exome sequencing.
  • 13.3.7. ASM Announces CDC-Funded Genomic Surveillance Training Program.
  • 13.3.8. The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market.
  • 13.3.9. Illumina launches next-generation DNA sequencers.
  • 13.3.10. Thermo Fisher Scientific Launches CE-IVD Marked Next-Generation Sequencing Instrument for Use in Clinical Labs.
  • 13.3.11. Illumina and Trivitron Partner to Accelerate Disease Detection and Diagnosis for Patients in India.
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 10x Genomics, Inc.
• 2. Agilent Technologies, Inc.
• 3. ATDBio Ltd.
• 4. BGI Genomics Co., Ltd.
• 5. Bio-Rad Laboratories, Inc.
• 6. BIO3 SCIENTIFIC SDN BHD
• 7. bioMerieux S.A.
• 8. BioVendor-Laboratorni medicina a.s
• 9. Cambridge Bioscience Limited
• 10. CD Genomics
• 11. CeGaT GmbH
• 12. Charles River Laboratories, Inc.
• 13. DNAnexus, Inc.
• 14. DNASTAR, Inc.
• 15. ELEMENT BIOSCIENCES
• 16. Enzo Life Sciences, Inc.
• 17. Eppendorf SE
• 18. Eurofins Scientific SE
• 19. F. Hoffmann-La Roche Ltd.
• 20. Fraunhofer-Gesellschaft
• 21. GENEWIZ
• 22. Genomatix
• 23. GenPath
• 24. GenScript Biotech Corporation
• 25. GRAIL, LLC
• 26. Hamilton Company
• 27. Illumina, Inc.
• 28. Integrated DNA Technologies, Inc.
• 29. Invivoscribe, Inc.
• 30. iRepertoire, Inc.
• 31. LabMal
• 32. Macrogen, Inc.
• 33. Medigene Sdn Bhd.
• 34. Merck KGaA
• 35. NanoString Technologies, Inc.
• 36. Neoscience
• 37. Norgen Biotek Corp.
• 38. Oxford Nanopore Technologies PLC
• 39. Pacific Biosciences of California, Inc.
• 40. PathoQuest
• 41. PCR Biosystems Ltd.
• 42. Perkin Elmer, Inc.
• 43. Promega Corporation
• 44. PT Pandu Biosains
• 45. Qiagen N.V.
• 46. Resolution Bioscience, Inc.
• 47. Takara Bio Inc.
• 48. Thermo Fisher Scientific Inc.